Assessment of Knowledge, Attitude and Perception of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting among the Pharmacy Students in South India

V. Lokesh Reddy¹, S.K. Javeed Pasha¹, Dr. Mohanraj Rathinavelu², Dr. Y. Padmanabha Reddy³

¹(Pharm.D Intern, Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research, India).

Abstract: The Study entitled "Assessment of Knowledge, Attitude and perception of Pharmacovigilance and Adverse Drug Reaction (ADR) Reporting among the Pharmacy Students in South India" was designed to assess the awareness of Pharmacovigilance and ADR reporting, and to evaluate the impact of an educational intervention. A validated (pilot study) self administered (KAP) Knowledge, attitude, perception survey questionnaire was used in the study. This prospective knowledge attitude practice (KAP) questionnaire study, of 6 month duration included a total of 225(90%) participants out of 250. An interactive educational intervention was designed for all participants of pre-KAP questionnaire survey. The impact of effectiveness of educational intervention among the pharmacy students was evaluated by means of post-KAP questionnaire survey. The paired t-test and chi-square test in GraphPad InStat was used for statistical calculation. The overall response rates between pre intervention and post intervention was statistically significant (P< 0.001) shows effectiveness of educational intervention for improving awareness of pharmacovigilance and ADR reporting among the participants. The study concluded that imparting the knowledge and awareness of Pharmacovigilance among the pharmacy students by means of continuous educational intervention would bring up updated knowledge and practice in drug safety and rational use.

Keywords: ADR reporting, Continuous Pharmacy Education, KAP questionnaire, Pharmacovigilance, Pharmacy Students.

I. Introduction

The safety of patients and the safe use of medicines are high requisitions in the modern world. In 1968, the first practical international co-operation in drug monitoring was established. The ideas came up as a consequence of the so called thalidomide tragedy. In the 1960's it was discovered that if thalidomide is ingested by mothers during pregnancy limb deformities in babies may occur. This incident became the modern starting point of a science focusing on patient problems due to medicinal use. Medication safety is a more significant issue, because of immense competition among pharmaceutical manufacturers; medicinal products may be registered and marketed in many countries simultaneously. As a result, adverse reactions may not always be readily identified and so are not monitored systematically.

Pharmacovigilance is a systematic and structured process for the monitoring and detection of adverse drug reactions (ADRs) in a given context [1]. Pharmacovigilance has constantly grown its importance in last 15 years, relating to the absolute amount of adverse drug reactions (ADRs) and to the fact of several hospital admissions are due to ADRs [4, 5]. Pharmacovigilance is an arm of patient care and surveillance. It aims at getting the best outcome from treatment with medicine. Adverse drug reactions (ADRs) are common causes of morbidity and mortality in both hospital and community settings. Adverse drug reactions (ADRs) are global problems of major concern. They affect both children and adults with varying magnitudes; causing morbidity and mortality [2-3, 7-8]. ADRs are responsible for about 5% to 20% of hospital admissions [2, 3].

World Health Organization (WHO) defines Pharmacovigilance "as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug related problems [6].Definitions of Adverse Drug Reactions (ADR) exist, including those of the World Health Organization (WHO) [6], Karch and Lasagna and the Food and Drug Administration (FDA).

World Health Organization (WHO) defines ADR as "any response to a drug which is noxious and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function".

²(Assistant Professor, Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research, India).

³⁽Professor and Principal, Department of Analysis, Raghavendra Institute of Pharmaceutical Education and Research, India). Forum

Studies from different settings indicate inadequate knowledge about pharmacovigilance among healthcare professionals as well as attitude that are associated with high degree of underreporting [9-14]. Pharmacovigilance is still in its infancy in India and there exists very limited knowledge about this discipline. The Pharmacovigilance Programme of India (PvPI) like most others around the world suffers from underreporting of ADRs by the healthcare professionals; this can delay the detection of important ADRs. However, the Indian national Pharmacovigilance programme lacks continuity due to lack of awareness and inadequate training about drug safety monitoring among healthcare professionals in India [15].

Assessment of awareness of Pharmacovigilance among the healthcare professionals is very important due to under reporting of adverse drug reactions. Although previous studies indicated that pharmacists are pivotal players in ADR monitoring and reporting, most pharmacists are unaware or not knowledgeable about the guidelines used by their respective countries, drug regulatory bodies responsible for assessing ADRs [16, 17].

As drug experts, pharmacists should be equipped with the skills to prevent, identify, and resolve drug related problems and counsel patients on drug therapy [18]. The involvement of pharmacists in pharmacovigilance programs is considered to be vital.Modern Pharmacists consider Pharmaceutical care as their prime focus and play an important role in patient care. Ensuring the safe use of drugs is a combined responsibility of the healthcare team that includes Doctors, Nurses, Pharmacists and other supporting staff [19].

As future pharmacy practitioners, pharmacy students need to be well trained on how to recognize, prevent and report ADRs. Therefore, the aim and objective of this study was to evaluate the perceptions of and knowledge about Pharmacovigilance and ADR reporting among pharmacy students at pharmacy colleges in South India by an interactive educational module as an intervention.

II. Methodology

2.1 Study design and site:

The six months prospective Knowledge Attitude Practice (KAP) Questionnaire based study was carried out in one of the reputed pharmacy institute of Andhra Pradesh, Raghavendra Institute of Pharmaceutical Education and Research, Andhra Pradesh, India, from January to June 2013.

2.2 Study sample:

A total of 225 students participated in the study, and they comprised of 111 male and 114 females. The study criteria included students of M.Pharmacy(Pharmaceutics, Pharmacology & Analysis Departments), Pharm.D (Doctor of Pharmacy) both regular(IV, V, and VI) and post baccalaureate (PB), and final year students of B.Pharmacy.

2.3 Design of Questionnaire:

The questionnaire was a 30 item inventory titled Standard KAP Questionnaire, the items were generated from the literature and adaptation from previous studies and a two step validation process was followed for its accuracy and uniqueness.

Initially, the questionnaire comprised of 36 inventories, modified to 30 in final by 02 step validation process.

In step 01, Questionnaire Validation three pharmacy lecturers with experience in drug use research and ADR reporting studies were asked to evaluate the clarity, relevance and conciseness of items included in the questionnaire (limitations on questionnaire was a feedback which was rectified by eliminating 6 questions which was felt more complex for the participants). The observations and comments of the lecturers were taken in to the account.

In step 02, Questionnaire validation to test the validity and reliability of the questionnaire, the survey form was pilot tested by administering it to sample of 15 pharmacy students who did not participate in the study. The overall Cronbach's alpha value calculated was 0.72, which required no further modifications in questionnaire.

The final KAP questionnaire (Annexure - 01) consisted of 30 questions out of which:

Section A: Includes 20 questions related to basic knowledge and information about pharmacovigilance.

Section B: Includes 05 questions related to student's attitude.

Section C: Includes 05 questions related to perception regarding identification of ADR and reporting nature.

2.4. Data collection:

Initially Pre-KAP questionnaire was administered and briefed to all participants about the purpose of the study and asked to submit the same. The Pre-KAP questionnaire was analyzed question wise and their percentage value was calculated. An interactive educational intervention was designed separately for all participants of Pre-KAP questionnaire survey in order to facilitate the transfer of knowledge of pharmacovigilance program. The educational intervention consisted of a theoretical presentation on what is pharmacovigilance, adverse drug reactions, history of pharmacovigilance, classification of ADRs, incidence of ADRs, mechanism of ADRs, role of HCP (health care professionals in-specific pharmacists), reporting of

suspected adverse drug reaction followed by economic and epidemiological importance of reporting the ADRs and its effect on patient safety and Classification of ADRs (i.e. in terms of causality assessment, seriousness and severity, ADR reporting cards from various countries, ADR alert cards). After the interactive educational intervention program on pharmacovigilance, all participants of Pre-KAP questionnaire in the study was administered with Post-KAP questionnaire and it was analyzed, question wise and their responses were documented.

2.5. Data Analysis and Statistics:

The filled KAP questionnaires were evaluated as per the study objectives. The various parameters such as sex distribution, professional status, educational qualifications, and the KAP scores were analyzed. The data obtained were entered in Microsoft excel spread sheet and evaluated. To measure changes in the awareness of pharmacovigilance among the pharmacy students between pre-intervention and post-intervention and to evaluate the impact of effectiveness of educational intervention among the pharmacy students, the chi-square test was used to compare the difference in correctness for each question. All results attained were entered in Microsoft excel and the statistical calculations were executed using GraphPad Instat Version 3.06. The level of statistical significance was set at p<0.05.

III. Results

The present study involved 225 (90%) pharmacy students out of 250, who participated and responded. Demographic details of the participants involved in the study was categorized based on gender distribution, educational qualification, and professional status, the results of which were thoroughly analyzed and reported in Table. 1.

Table. 1. Demographic detail of the participants

S. no	Demographic details	No. of Participants		
		(n = 225)		
01	Gender Distribution	Male	Female	
		111 (49.3%)	114 (50.7%)	
02	Education Qualification	No. of	Gender distribution	
		students	Male	Female
		(n = 225)		
	A. B. Pharmacy	69	27	42
		(30.67%)	(39.1%)	(60.8%)
	B. M. Pharmacy	55	22	33
		(24.44%)	(40%)	(60%)
	C. Pharm. D	79	45	34
		(35.11%)	(56.9%)	(43.1%)
	D. Pharm. D	22	17	05
	(post baccalaureate)	(9.78%)	(77.3%)	(22.7%)
03	Professional Status	Pharmacy Stud	lents	

The response of the study was evaluated by administering a standard KAP Questionnaire to all the 225 participants, to assess their knowledge attitude and perception/practice towards pharmacovigilance and ADR reporting by comparative study between Pre-KAP & Post-KAP percentage of positive responses.

All the values and percentage of positive and negative responses for the KAP questionnaire, (Pre-KAP & Post-KAP) comprising of 30 questions was evaluated and tabulated in Table. 2.

Table. 2. Knowledge, attitude, perception of pharmacy students towards Pharmacovigilance& ADR reporting Questionnaire before & after educational intervention.

Q. no	K A P Items	Pre – KAP responses (%) N = 225	Post – KAP responses (%) N = 225	p- value
01.	Pharmacovigilance is the study that relates to			
	Safe, effective, appropriate and economic use of medicines	13 (5.88%)	03 (1.33%)	
	Therapeutic drug monitoring	25 (11.11%)	05 (2.22%)	
	Detection, assessment, understanding & prevention of adverse	174 (77.33%)	209 (92.88%)	< 0.001
	effects*			
	All.	13 (5.88%)	08 (3.55%)	
02.	The functions of Pharmacovigilance are:			
	Detection and study of ADRs.	63 (28%)	26 (11.55%)	
	Measurement of risk and effectiveness of drug use.	11 (4.88%)	13 (5.77%)	
	Dissemination of ADR information and education	11 (4.88)	13 (5.77%)	
	All of the above.*	140 (62.2%)	173 (76.83%)	< 0.001

03.	Pharmacovigilance includes:			
	Drug related problem.	32(14.2%)	26 (11.55%)	
	Herbal products	19(8.44%)	11 (4.9%)	
	Medical devices & vaccines.	40(17.77%)	26 (11.55%)	
	All.*	134 (59.55%)	162 (72%)	0.007
04.	National Pharmacovigilance Programme (NPP) of India was			
	officially inaugurated in the year:			
	Ghaziabad, 2002	21 (9.33%)	04 (1.77%)	
	Mumbai, 2008	18 (08%)	06 (2.66%)	
	New Delhi, 2004*	154 (8.44%)	212 (94.22%)	< 0.001
	Kolkata, 2006	32 (14.22%)	03 (1.33%)	
05.	National pharmacovigilance program in India is governed by:	11 (5 220)	227 (1000)	0.004
	CDSCO under the aegis of Health and Family Welfare*	14 (6.22%)	225 (100%)	< 0.001
	Medical Council of India & ICMR	33 (14.66%)	00	
	Pharmacy Council of India	157 (9.77%)	00	
06.	Pharmacovigilance program in India comprises of how many			
	members			
	17	16 (7.11%)	08 (3.55%)	
	13	193 (85.77%)	13 (5.77%)	
	10*	13 (5.77%)	201 (89.33%)	< 0.001
	11	03 (1.33%)	03 (1.33%)	
07.	The International centre of Adverse Drug Reaction monitoring is			
	located in United States of America	07 (/2 110/ \	03 (1 220/)	
	France	97 (43.11%) 27 (12%)	03 (1.33%)	
	Australia	49 (21.7%)	00	
	Sweden*	52 (23.11%)	222 (98.66%)	< 0.001
08.	AIIMS New Delhi is a:	32 (23.1170)	222 (20.0070)	<0.001
00.	Peripheral pharmacovigilance centre.	13 (5.77%)	02 (0.88%)	
	Zonal pharmacovigilance centre.*	25 (11.11%)	209 (92.88%)	< 0.001
	Regional pharmacovigilance centre.	94 (41.77%)	05 (2.22%)	(0.001
	National pharmacovigilance centre.	93 (41.33%)	09 (4.0%)	
09.	Hierarchy of Pharmacovigilance centers in India comprises of	70 (1510070)	05 (11070)	
	following:			
	Zonal, regional & peripheral.*	86 (38.22%)	184 (81.77%)	< 0.001
	Peripheral, zonal & regional	41 (18.22%)	11 (4.88%)	
	Regional, zonal & peripheral.	65 (28.88%)	12 (5.33%)	
	None of the above	33 (14.66%)	18 (8.0%)	
10.	One among these is a regional pharmacovigilance centre:			
	Kasturba Hospital Manipal.	11 (4.88%)	02 (0.88%)	
	JIPMER, Pondicherry*	13 (5.77%)	211 (93.77%)	< 0.001
	JSS Medical College & Hospital, Mysore	90 (8.44)	04 (1.76%)	
	CMC, Vellore.	111 (49.33%)	08 (3.55%)	
11.	The order ADR report submission is:			
	PPC - RPC - ZPC*	54 (24.0%)	162 (72.0%)	< 0.001
	RPC – PPC – ZPC	69 (30.66%)	21 (9.33%)	
	ZPC – RPC – PPC	32 (14.22%)	24 (10.66%)	
10	Any order.	70 (31.11%)	18 (8.0%)	
12.	Peripheral centers in National Pharmacovigilance India 27	76 (33.77%)	46 (20.44%)	
	26		67 (29.77%)	
	28*	45 (20.0%) 56 (24.88%)	140 (62.22%)	< 0.001
	29	48 (21.33%)	28 (10.66%)	\0.001
13.	The chairman of Pharmacovigilance program in India	TO (21.3370)	20 (10.00%)	+
10.	DCGI (Drug Controller General of India).*	54 (24.0%)	188 (83.55%)	< 0.001
	Scientific Director, Indian Pharmacopeia Commission, Ghaziabad.	111 (49.33%)	23 (10.22%)	\0.001
	Nominee of Director General, ICMR	34 (15.11%)	10 (4.44%)	
	Nominee of Pharmacy Council of India	26 (11.55%)	04 (1.76%)	
14.	ADR reporting form are periodically reviewed by	. (/ ")	(=:: =/=)	
	National Advisory Committee.*	66 (29.33%)	175 (77.77%)	< 0.001
	National Co-coordinating Committee.	78 (34.66%)	56 (24.88%)	
		25 (37.77%)	18 (08)	
	Steering Committee	23 (31.11/0)		
	All of the above	56 (24.88%)	24 (10.66%)	
15.	All of the above According to Wills & Brown, how many types of ADRs are		24 (10.66%)	
15.	All of the above According to Wills & Brown, how many types of ADRs are classified	56 (24.88%)	,	
15.	All of the above According to Wills & Brown, how many types of ADRs are classified 06	56 (24.88%) 54 (24.0%)	36 (16.0%)	
15.	All of the above According to Wills & Brown, how many types of ADRs are classified 06 07	56 (24.88%) 54 (24.0%) 33 (14.66%)	36 (16.0%) 21 (9.33%)	
15.	All of the above According to Wills & Brown, how many types of ADRs are classified 06	56 (24.88%) 54 (24.0%)	36 (16.0%)	<0.001

		1		
16.	Match the following ADRs:			
	Streptomycin – Phocomelia Thalidomide – Psychosis			
	Ofloxacin – Deafness ii, i & iii.	49 (21.77%)	25 (11.11%)	
	ii, i & ii.	65 (28.88%)	11 (4.88%)	
	iii, i & ii.*	76 (33.77%)	189 (84%)	< 0.001
	None of the above.	35 (15.55%)	00	<0.001
17.	ADRs which are independent can be treated:	33 (13.3370)	00	
1/.	By withdrawing the drug.*	146 (64.88%)	203 (90.22%)	<0.001
	By reducing the dose	54 (24.0%)	18 (8.0%)	<0.001
	Replacing the medications.	25 (11.11%)	04 (1.77%)	
	All of the above	00	00	
	Thi of the doore	00		
	Augmented drug reaction is			
18.				
10.	Dose dependent, common in occurrence, rarely fatal.*	129 (57.33%)	197 (87.55%)	<0.001
	Dose independent, common in occurrence, rarely ratar. Dose independent, comparatively rare in occurrence, more fatal.	87 (38.66%)	28 (12.44%)	<0.001
	Both of above.	05 (2.22%)	00	+
	None of the above	04 (1.76%)	00	+
	None of the above	04 (1.70%)	00	
19.	Which one of the following is the "WHO online databases" for			
17.	reporting ADRs			
	ADR advisory committee.	86 (38.22%)	11 (4.88%)	
	Medsafe	19 (8.44%)	9 (4.0%)	
	Vigibase.*	57 (25.33%)	199 (88.44%)	< 0.001
	Med watch	63 (28.0%)	06 (2.66%)	10.001
20.	Match the ADR reporting system to the respective countries:	05 (20.070)	00 (2.0070)	
	Yellow card - India			
	Green card - Australia			
	ADR reporting form - UK			
	Blue card - Scotland			
	iii, iv, i ii*	45(20%)	178(79.11%)	< 0.001
	iv. iii, ii, i	62(27.55%)	32(14.22%)	
	ii, i, iii, iv	106(47.11%)	25(11.11%)	
	i, ii, iii, iv	12(5.33%)	10(4.44%)	
21.	The health care professionals responsible for ADR reporting in a			
	hospital is/are:			
	Doctor	57(25.33%)	01(0.44%)	
	Pharmacist	146(64.88%)	19(8.44%)	
	Nurses	12(5.33%)	00	
	All of the above*	10(4.44%)	205(91.11%)	< 0.001
22.	Do you think reporting is a professional obligation to you			
	Yes*	90(40%)	187(83.11%)	< 0.001
	No	76(33.77%)	32(14.22%)	
	Don't Know	53(23.55%)	00	
22	Perhaps	06(2.66%)	06(2.66%)	
23.	What is your opinion about establishing ADR monitoring centre in			
	every hospital:	115/51 110/	105(02.220()	0.001
	Should be in every hospital.*	115(51.11%)	185(82.22%)	< 0.001
	One in a city is sufficient	70(31.11%)	12(5.33%)	
	Not necessary in every hospital	45(20%)	27(12%) 01(0.44%)	
24	Depends on bed size Do you think reporting of ADRs is necessary	05(2.22%)	01(0.44%)	
24.		205(01 110/)	225(1000/)	<0.001
	Yes*	205(91.11%)	225(100%)	< 0.001
25	No	20(8.88%)	00	
25.	Do you think Pharmacovigilance should be taught in detail to healthcare professionals:			
	Yes*	215(95.55%)	224(99.55%)	0.014
	No	10(4.44%)	01(0.44%)	0.014
	110	10(7.7770)	01(0.4470)	
26.	Have you ever come across with an ADR			
	Yes*	69(30.66%)	135(60%)	<0.001
	No	156(69.33%)	90(40%)	\0.001
27.	Have you ever been came across educational session in specific	130(03.33%)	7U(4U%)	
21.	about pharmacovigilance:			
	Yes*	76(33.77%)	225(100%)	< 0.001
	No No	149(66.22%)	00	VO.001
	1 ***	117(00.22/0)	1 00	

28.	Have you anytime read any article on prevention of ADRs:			
	Yes*	18(8%)	20(8.88%)	0.865
	No	207(92%)	205(91.11%)	
29.	Have you ever been trained on how to report ADRs:			
	Yes*	47(20.88%)	225(100%)	< 0.001
	No	178(79.11%)	0	
30.	Non medical person can report ADR to a nearby Healthcare professional			
	Yes*	58(25.77%)	221(98.22%)	< 0.001
	No	167(74.22%)	04(1.77%)	

Correct Response*

P < 0.001- (comparison between the pre- KAP and Post- KAP responses).

From the above Results, it was analyzed that the response rate was statistically more significant with a p-value of p<0.001 for most of all the questions.

IV. Discussion

To the best of our knowledge, this was the first study in India that evaluated the knowledge, attitude, perception and practice of Pharmacovigilance among the pharmacy students, in a pharmacy Institute of South India (Andhra Pradesh). The study among the pharmacy students (UG, PG and Pharm.D) showed an overall response rate of 90%, this numeral can be regarded as very high, especially when compared with those of other studies on the same topic carried out among pharmacy students. The response rate attained was within the accepted range for survey research. In order to maximize the response rate and minimize response bias, the questionnaire was administered personally to the participants by the facilitator [20, 21].

The study showed that participants (pharmacy students) who attended the interactive educational intervention session on Pharmacovigilance and ADR reporting were much satisfied, and considered more effective and valuable. In our study, one focus of educational intervention was to increase the participant's (pharmacy students) awareness to Pharmacovigilance topics, regulatory body responsible for monitoring of ADRs, and the International- scenario on Pharmacovigilance. This educational intervention program encouraged the participants (pharmacy students) to pursue career in Pharmacovigilance as their future perspective.

This was demonstrated by an increase in the positive response in pre and post-KAP Questions (1 to 20) of the standard KAP questionnaire. Evidently, the documented results of question 05, was 6.22% to 100% after the intervention, which strongly suggested pharmacists are in need of information regarding the Pharmacovigilance Program of India (PVPI).

Question 13 from table 02 shows that 24% before pre-KAP to 83.55% post-KAP suggests that there is great need to create awareness and promote the governing authorities of PVPI, India. Question 07 & 08 from table 02 framed to obtain the information about the International and National scenario on ADR reporting system, where there was an increased positive response rate of 23.11% before to 98.66% after the educational intervention program as pre-KAP and post-KAP values respectively & 11.11% before to 92.88% after the intervention. The result strongly suggests educating pharmacy students about the reporting systems of ADRs both of National and International standards [21]. The study secondarily focused on improvising the approach on Pharmacovigilance and ADR reporting among the pharmacy students, which was attained to the optimum best by comparing the positive responses of both pre-KAP and post-KAP values and it was statistically significant. Question 21 and 24 of table 02 emphasized on role of health care professionals on ADR reporting, for which the comparativeness with educational intervention in between pre-KAP and post-KAP defined effective and statistically significant.

Question 21 from table 02 showed that 4.44% before pre-KAP to 91.11% post-KAP strongly suggests that there is a great need to create promotion and awareness on ADR reporting among pharmacy students. The study finally focused on assessing the perception and practice of Pharmacovigilance and ADR reporting in the participants (pharmacy students), which was attained to an optimum best with 90% overall, with an exceptional of statistical insignificant response for question 28, which strongly suggests that students and professionals of pharmacy field to attend regularly the continuing pharmacy education programs on Pharmacovigilance [22]. Question 26 from table 02 shows response rate from 30.66% pre-KAP to 60% post-KAP which strongly suggests that the information, updation and practical knowledge on ADR were deficit.

Question 27 and question 29 from table 02 shows that there was reduced exposure on pharmacovigilance and ADR reporting from participants, due to lack in availability of facilitators expertise in delivering education sessions on pharmacovigilance. This study overcomes the above mentioned limitation to satisfactorial extent, with significant positive and statistical responses.

V. Conclusion

In conclusion, the results of the present study demonstrates that an educational intervention can increase awareness of pharmacovigilance among the participants (pharmacy students) and incorporate this gained knowledge of pharmacovigilance for opting career and routine clinical practice.

This study has important limitation that the number of students participated in this study was relatively small considering the number of students currently enrolled in the study site. Therefore, these results may not necessarily be extrapolated to all pharmacy students and pharmacy Institute. We recommend that several such studies of similar kind should be conducted among other Institutions so as to develop strategies to improve the knowledge, attitude and perception of pharmacovigilance in India.

This survey on pharmacovigilance and ADR reporting among pharmacy students in south India suggests that the pharmacy students in this country may lack in-depth understanding of the facts about ADR reporting and may need more information on the National Pharmacovigilance System and ADR reporting process. Pharmacy student's education should include topics related to the methods of detecting, preventing, and reporting of ADRs to enable and play vital role in prevention of ADRs through their interactions with both prescribers and patients.

Acknowledgements

The authors would like to thank all faculties of Raghavendra Institute of Pharmaceutical Education and Research (RIPER) and Dr. MohanrajRathinavelu, Assistant Professor, Department of Pharmacy Practice, RIPER for their valuable guidance and constant support.

References

- [1]. WHO policy perspectives on medicines. Pharmacovigilance: ensuring the safe use of medicines. Geneva: world health organization; 2004, available from http://www.who.int/medicines/.
- [2]. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta analysis of prospective studies. *Journal of the American Medical Association*, 279(15), 1998, 1200-1205.
- [3]. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. *British Medical Journal*, 329(7456):15, 2004.
- [4]. Von Laue NC, Schwappach DL, Koeck CM. The epidemiology of preventable adverse drug events: a review of literature. *Wien KlinWochenschr*, 115(12), 2003, 407-415.
- [5]. Wu WK, Pantaleo N et al Evaluation of outpatient adverse drug reactions leading to hospitalization. American Journal of Health System Pharmacy, 60(3), 2003, 253-259.
- [6]. www.WHO.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/ (accessed January 2012).
- [7]. Oshikoya KA, Adverse drug reaction in children: types, incidence and risk factors, Nigerian Journal of Pediatrics, 33, 2006, 29-35.
- [8]. Martinez-Mir I, Garcia-Lopez M, Palop V, Ferrer JM, Rubio E, Morales-Olivas FJ, A prospective study of adverse drug reactions in hospitalized children, *British Journal of Clinical Pharmacology*, 47, 1999, 681 688.
- [9]. Figueiras A, Tato F, Fontainas J, Gestal-Otero JJ et al: Influence of physicians' attitudes on reporting adverse drug events: a case-control study. *Medical Care*, *37*(8), 1999, 809-814.
- [10]. Williams D, Feely J. Underreporting of adverse drug reactions: attitudes of Irish doctors. *Irish Journal of Medical Science*, 168, 1999, 257-261.
- [11]. Perlik F, Slanar O, Smid M, Petracek J et al: Attitude of Czech physicians to adverse drug reaction reporting, *European Journal of Clinical Pharmacology*, 58, 2002; 367-369.
- [12]. Belton KJ, Lewis SC, Payne S, Rawlins MD et al: Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom, *British Journal of Clinical Pharmacology*, 39, 1995, 223- 226.
- [13]. Hasford J, Goettler M, Munter KH, Muller-Oerlinghausen B et al: Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions, *Journal of Clinical Epidemiology*, 55, 2002, 945-950.
- [14]. Herdeiro MT, Figueiras A, Polo´ nia J, Gestal- Otero JJ et al. Physicians' attitudes and adverse drug reaction reporting: a case-control study in Portugal, *Drug Saf*, 28, 2005; 825-833.
- [15]. Rajesh R, Vidyasagar S, Nandakumar K et al: Highly active antiretroviral therapy induced adverse human immunodeficiency virus positive patients, *Journal of advanced Pharmaceutical Technology and Research*, ; 9(1), 2011 Jan-Mar:48-55.
- [16]. Vallano A, Cereza G, Pedros C, et al. Obstacles and solutions for spontaneous reporting of adverse drug reactions in the hospital. *British Journal of Clinical Pharmacology*, 60(6), 2005, 653.
- [17]. Backstrom M, Mjorndal T, Dahlqvist R et al: Under-reporting of serious adverse drug reactions in Sweden. Journal of Pharmacoepidemiology and Drug Safety, 13(7), 2004, 483-487.
- [18]. Hassali M, Kong D, Stewart K et al: Knowledge and perceptions of recent pharmacy graduates about generic medicines, *Pharmacy Education*, 7(1), 2007, 89.
- [19]. Hepler CD. Clinical pharmacy, pharmaceutical care, and the quality of drug therapy, *PUBMED* (*Pharmacotherapy*), 24, 2004; 1491-8.
- [20]. Lydeard S. Commentary: avoid surveys masquerading as research. British Medical Journal, 313(7059), 1996, 733-734.
- [21]. Hartge P. Raising response rates: getting to yes. *Epidemiology*, 10(2), 1999; 105-107.
- [22]. Figueiras A, Herdeiro MT, Polonia J, and Gestal -Otero JJ: An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. *Journal of the American Medical Association*, 296, 2006, 1086-1093.

nnexure 1
KAP (Knowledge, Attitude &Perception) Questionnaire 01. Pharmacovigilance is the study that relates to: Safe, effective, appropriate and economic use of medicines. Therapeutic drug monitoring. Detection, assessment, understanding & prevention of adverse effects. All.
02. The functions of Pharmacovigilance are: ☐ Detection and study of ADRs. ☐ Measurement of risk and effectiveness of drug use. ☐ Dissemination of ADR information and education. ☐ All of the above.
03. Pharmacovigilance includes: Drug related problem. Herbal products Medical devices and vaccines. A
04. National Pharmacovigilance Programme (NPP) of India was officially inaugurated in the year: Ghaziabad, 2002 Mumbai, 2008 New Delhi, 2004 Kolkata, 2006
 05. National pharmacovigilance programme in India is governed by: CDSCO under the aegis of Health and Family Welfare. Medical Council of India & ICMR. Pharmacy Council of India. None of the above.
06. Pharmacovigilance programme in India comprises of how many members: ☐ 17 ☐ 13 ☐ 10 ☐ 11
07. The International centre of Adverse Drug Reaction monitoring is located in: United States of America Australia Sweden
08. AIIMS New Delhi is a: Peripheral pharmacovigilance centre. Zonal pharmacovigilance centre. Regional pharmacovigilance centre. National pharmacovigilance centre.
 09. Hierarchy of Pharmacovigilance centres in India comprises of following: Zonal, regional & peripheral. Peripheral, zonal& regional. Regional, zonal& peripheral. None of the above.
 10. One among these is a regional pharmacovigilance centre: Kasturba Hospital Manipal. JIPMER, Pondicherry. JSS Medical College & Hospital, Mysore. CMC, Vellore.

11. The order ADR report submission is: PPC - RPC - ZPC. RPC - PPC - ZPC. ZPC - RPC - PPC. Any order.
12. Peripheral centres in National Pharmacovigilance India: 27
 13. The chairman of Pharmacovigilance programme in India: DCGI (Drug Controller General of India). Scientific Director, Indian Pharmacopeia Commission, Ghaziabad. Nominee of Director General, ICMR. Nominee of Pharmacy Council of India.
 14. ADR reporting form are periodically reviewed by: National Advisory Committee. National Co-ordinating Committee. Steering Committee. All of the above.
15. According to Wills & Brown, how many types of ADRs are classified: 6 7 8 9
 16. Match the following ADRs: i. Streptomycin – Phocomelia ii. Thalidomide – Psychosis iii. Ofloxacin – Deafness ii, i & iii. iii, ii & ii. iii, ii & i. iii, i & ii. None of the above.
17. ADRs which are independent can be treated: By withdrawing the drug. By reducing the dose. Replacing the medications. All of the above.
 18. Augmented drug reaction is: Dose dependent, common in occurrence, rarely fatal. Dose independent, comparatively rare in occurrence, more fatal. Both of above. None of the above.
 19. Which one of the following is the "WHO online databases" for reporting ADRs: ADR advisory committee. Medsafe. Vigibase. Med watch.
20. Match the ADR reporting system to the respective countries: (write the number in appropriate boxes) i. Yellow card
21. The health care professionals responsible for ADR reporting in a hospital is/are: Doctor Pharmacist Nurses All of the above

22. Do you think reporting is a professional o	bligation to you: Don't Know	Perhaps		
23. What is your opinion about establishing A Should be in every hospital. One in a city is sufficient. Not necessary in every hospital. Depends on bed size. 24. Do you think reporting of ADRs is necess Yes No		every hospital:		
25. Do you think Pharmacovigilance should by Yes No	oe taught in detail to healt	chcare professionals:		
26. Have you ever come across with an ADR Yes No	:			
27. Have you ever been trained on how to report Adverse Drug Reaction: ☐ Yes ☐ No				
28. Have you anytime read any article on pred Yes No	vention of ADRs:			
29. Have you ever been trained on how to report ADRs: Yes No				
30. Non medical person can report ADR to a nearby Healthcare professional: Yes No				
rticipant's details:				
Name of the student Gender				
Professional status	Professional status			
Educational qualification				